Rheumatic heart disease: A review of the current status of global research activity.

[1]  J. Carapetis,et al.  Single Parasternal-Long-Axis-View-Sweep Screening Echocardiographic Protocol to Detect Rheumatic Heart Disease: A Prospective Study of Diagnostic Accuracy. , 2020, Heart, lung & circulation.

[2]  G. Schett,et al.  Microbiota and metabolites in rheumatic diseases. , 2020, Autoimmunity reviews.

[3]  N. Petrovsky,et al.  Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies , 2020, mBio.

[4]  L. Whittles,et al.  Naturally-acquired protection against upper respiratory symptoms involving group A Streptococcus in a longitudinal cohort study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  W. M. Hussein,et al.  Polyacrylate–Peptide Antigen Conjugate as a Single-Dose Oral Vaccine against Group A Streptococcus , 2020, Vaccines.

[6]  P. Hotez,et al.  What constitutes a neglected tropical disease? , 2020, PLoS neglected tropical diseases.

[7]  J. Langley,et al.  Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. , 2019, Vaccine.

[8]  N. Geard,et al.  Longitudinal analysis of group A Streptococcus emm types and emm clusters in a high prevalence setting reveals past infection does not prevent future infection. , 2019, The Journal of infectious diseases.

[9]  T. Merriman,et al.  Risk Factors for Acute Rheumatic Fever: Literature Review and Protocol for a Case-Control Study in New Zealand , 2019, International journal of environmental research and public health.

[10]  K. Sliwa,et al.  Genetics of rheumatic fever and rheumatic heart disease , 2019, Nature Reviews Cardiology.

[11]  G. Tyrrell,et al.  Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice , 2019, Science Advances.

[12]  M. Cunningham.  Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae , 2019, Microbiology spectrum.

[13]  V. Fischetti.  Surface Proteins on Gram-Positive Bacteria. , 2019, Microbiology spectrum.

[14]  M. C. Nunes,et al.  Circulating cytokines predict severity of rheumatic heart disease. , 2019, International journal of cardiology.

[15]  A. Steer,et al.  The Limitations of the Rheumatogenic Concept for Group A Streptococcus: Systematic Review and Genetic Analysis. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  L. Guilherme,et al.  Group A Streptococcus Adsorbed Vaccine: Repeated Intramuscular Dose Toxicity Test in Minipigs , 2019, Scientific Reports.

[17]  A. Ralph,et al.  Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease , 2019, PLoS neglected tropical diseases.

[18]  W. M. Hussein,et al.  Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems against Group A Streptococcus , 2019, Vaccines.

[19]  J. McCarthy,et al.  Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. , 2019, Vaccine.

[20]  V. Nizet,et al.  An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model , 2019, mBio.

[21]  D. Sexton,et al.  Ficolins and the Recognition of Pathogenic Microorganisms: An Overview of the Innate Immune Response and Contribution of Single Nucleotide Polymorphisms , 2019, Journal of immunology research.

[22]  Jerome H. Kim,et al.  The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  K. Sliwa,et al.  Momentum builds for a global response to rheumatic heart disease. , 2018, European heart journal.

[24]  J. Carapetis,et al.  The Cost of Inaction on Rheumatic Heart Disease in Australia , 2018, Heart, Lung and Circulation.

[25]  T. Speed,et al.  Dysregulated IL-1&bgr;-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine , 2018, Circulation.

[26]  J. Anaya,et al.  Molecular mimicry and autoimmunity. , 2018, Journal of autoimmunity.

[27]  S. Shulman,et al.  Caution Indicated in Extrapolating Carditis in Rats to Rheumatic Heart Disease in Humans. , 2018, The Journal of infectious diseases.

[28]  K. Sliwa,et al.  Time to tackle rheumatic heart disease: Data needed to drive global policy dialogues , 2018, Global public health.

[29]  J. Carapetis,et al.  Ascertaining infectious disease burden through primary care clinic attendance among young Aboriginal children living in four remote communities in Western Australia , 2018, PloS one.

[30]  A. Ralph,et al.  Improving Delivery of Secondary Prophylaxis for Rheumatic Heart Disease in a High‐Burden Setting: Outcome of a Stepped‐Wedge, Community, Randomized Trial , 2018, Journal of the American Heart Association.

[31]  J. McCarthy,et al.  Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial , 2018, PloS one.

[32]  L. Guilherme,et al.  Acute rheumatic fever , 2018, The Lancet.

[33]  R. S. Simpson,et al.  Group G Streptococcus Induces an Autoimmune Carditis Mediated by Interleukin 17A and Interferon &ggr; in the Lewis Rat Model of Rheumatic Heart Disease , 2018, The Journal of infectious diseases.

[34]  Manisha Pandey,et al.  Contribution of cryptic epitopes in designing a group A streptococcal vaccine , 2018, Human vaccines & immunotherapeutics.

[35]  A. Ralph,et al.  The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: A systematic review , 2018, PLoS neglected tropical diseases.

[36]  V. Nizet,et al.  Group A Streptococcus M1T1 Intracellular Infection of Primary Tonsil Epithelial Cells Dampens Levels of Secreted IL-8 Through the Action of SpyCEP , 2018, Front. Cell. Infect. Microbiol..

[37]  Manisha Pandey,et al.  Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy , 2018, npj Vaccines.

[38]  Y. Herry.  P325Statin inhibits synthesis of type I collagen in patients with rheumatic heart disease , 2018 .

[39]  E. Baker,et al.  Protein adhesins as vaccine antigens for Group A Streptococcus. , 2018, Pathogens and disease.

[40]  M. Maślińska,et al.  Rheumatic fever – new diagnostic criteria , 2018, Reumatologia.

[41]  A. Poppas,et al.  Rheumatic Heart Disease in Pregnancy: Global Challenges and Clear Opportunities , 2018, Circulation.

[42]  A. Ralph,et al.  Aboriginal children and penicillin injections for rheumatic fever: how much of a problem is injection pain? , 2018, Australian and New Zealand journal of public health.

[43]  N. Sharma,et al.  T cell subsets: an integral component in pathogenesis of rheumatic heart disease , 2017, Immunologic Research.

[44]  C. Longenecker,et al.  Latent Rheumatic Heart Disease: Identifying the Children at Highest Risk of Unfavorable Outcome , 2017, Circulation.

[45]  Manisha Pandey,et al.  Cellular interactions of covR/S mutant group A Streptococci. , 2017, Microbes and infection.

[46]  Mei-Fong Ho,et al.  Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial , 2017, Scientific Reports.

[47]  Manisha Pandey,et al.  Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen , 2017, The Journal of Immunology.

[48]  M. Inouye,et al.  Genome-wide analysis of genetic risk factors for rheumatic heart disease in Aboriginal Australians provides support for pathogenic molecular mimicry , 2017, bioRxiv.

[49]  Andrea Beaton,et al.  Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015 , 2017, The New England journal of medicine.

[50]  T. Proft,et al.  Mucosal vaccination with pili from Group A Streptococcus expressed on Lactococcus lactis generates protective immune responses , 2017, Scientific Reports.

[51]  N. Wilson,et al.  Acute Rheumatic Fever After Group A Streptococcus Pyoderma and Group G Streptococcus Pharyngitis. , 2017, The Pediatric infectious disease journal.

[52]  A. Bowen,et al.  Are scabies and impetigo “normalised”? A cross-sectional comparative study of hospitalised children in northern Australia assessing clinical recognition and treatment of skin infections , 2017, PLoS neglected tropical diseases.

[53]  R. Kumar,et al.  Association of rheumatic fever & rheumatic heart disease with plausible early & late-stage disease markers , 2017, The Indian journal of medical research.

[54]  C. Deane,et al.  Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania , 2017, Nature Communications.

[55]  Yee‐Shin Lin,et al.  Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection , 2017, PloS one.

[56]  G. Morefield,et al.  Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes , 2017, The AAPS Journal.

[57]  V. Nizet,et al.  Group A Streptococcal M1 Protein Provides Resistance against the Antimicrobial Activity of Histones , 2017, Scientific Reports.

[58]  Jeremy C. Smith,et al.  Structure-based design of broadly protective group a streptococcal M protein-based vaccines. , 2017, Vaccine.

[59]  Mei-Fong Ho,et al.  Novel platform technology for modular mucosal vaccine that protects against streptococcus , 2016, Scientific Reports.

[60]  S. Ghosh,et al.  OS 01-07 CLINICAL IMPORTANCE OF COLLAGEN METABOLISM MARKERS IN RHEUMATIC HEART VALVE DISEASE IN INDIAN SUBPOPULATION , 2016, Journal of hypertension.

[61]  J. Carapetis,et al.  The inequitable burden of group A streptococcal diseases in Indigenous Australians , 2016, The Medical journal of Australia.

[62]  T. Merriman,et al.  Association study involving polymorphisms in IL-6, IL-1RA, and CTLA4 genes and rheumatic heart disease in New Zealand population of Māori and Pacific ancestry. , 2016, Cytokine.

[63]  J. McCarthy,et al.  Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate , 2016, Human vaccines & immunotherapeutics.

[64]  S. Colquhoun,et al.  Screening-detected rheumatic heart disease can progress to severe disease , 2016, Heart Asia.

[65]  A. Hofmann,et al.  Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate , 2016, PloS one.

[66]  J. Carapetis,et al.  Status of research and development of vaccines for Streptococcus pyogenes. , 2016, Vaccine.

[67]  V. Fischetti,et al.  One More Disguise in the Stealth Behavior of Streptococcus pyogenes , 2016, mBio.

[68]  Manisha Pandey,et al.  Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci , 2016, The Journal of Immunology.

[69]  M. Good,et al.  Cryptic epitope for antibodies should not be forgotten in vaccine design , 2016, Expert review of vaccines.

[70]  T. Proft,et al.  Streptococcal Superantigens: Biological properties and potential role in disease , 2016 .

[71]  Manisha Pandey,et al.  Streptococcus pyogenes: Basic Biology to Clinical Manifestations: Current Approaches to Group A Streptococcal Vaccine Development. , 2016 .

[72]  A. Ralph,et al.  Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trial , 2016, Trials.

[73]  G. Karthikeyan,et al.  Acute rheumatic fever and rheumatic heart disease , 2015, Nature Reviews Disease Primers.

[74]  L. Guilherme,et al.  Editorial: Frontiers in Autoimmune Disease: Rheumatic Fever and Rheumatic Heart Disease , 2015, Front. Pediatr..

[75]  G. Tyrrell,et al.  Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci , 2015, Expert review of vaccines.

[76]  R. Saginur,et al.  Acute rheumatic fever in First Nations communities in northwestern Ontario: Social determinants of health "bite the heart". , 2015, Canadian family physician Medecin de famille canadien.

[77]  R. Speare,et al.  Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community , 2015, PLoS neglected tropical diseases.

[78]  G. Maguire,et al.  Rheumatic heart disease in Indigenous children in northern Australia: differences in prevalence and the challenges of screening , 2015, The Medical journal of Australia.

[79]  J. Christensen,et al.  Adaptive Immunity against Streptococcus pyogenes in Adults Involves Increased IFN-γ and IgG3 Responses Compared with Children , 2015, The Journal of Immunology.

[80]  J. Carapetis,et al.  Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians , 2015, Journal of the American Heart Association.

[81]  E. Latz,et al.  TLR8 Senses Bacterial RNA in Human Monocytes and Plays a Nonredundant Role for Recognition of Streptococcus pyogenes , 2015, The Journal of Immunology.

[82]  Manisha Pandey,et al.  A Synthetic M Protein Peptide Synergizes with a CXC Chemokine Protease To Induce Vaccine-Mediated Protection against Virulent Streptococcal Pyoderma and Bacteremia , 2015, The Journal of Immunology.

[83]  A. Adler,et al.  Anti-inflammatory treatment for carditis in acute rheumatic fever. , 2015, The Cochrane database of systematic reviews.

[84]  A. Bolger,et al.  Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography: A Scientific Statement From the American Heart Association , 2015, Circulation.

[85]  Judith M. Martin.  The Mysteries of Streptococcal Pharyngitis , 2015, Current Treatment Options in Pediatrics.

[86]  Yundai Chen,et al.  A normal polymorphism site of TLR2 3′ untranslated region is related to rheumatic heart disease by up-regulating TLR2 expression , 2014, Annals of clinical biochemistry.

[87]  A. Boldt,et al.  Association of MASP2 polymorphisms and protein levels with rheumatic fever and rheumatic heart disease. , 2014, Human immunology.

[88]  E. Wald,et al.  The Group A Streptococcal Carrier State Reviewed: Still an Enigma. , 2014, Journal of the Pediatric Infectious Diseases Society.

[89]  Michael W Parker,et al.  A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. , 2014, The Journal of infectious diseases.

[90]  N. Ketheesan,et al.  Animal Models to Investigate the Pathogenesis of Rheumatic Heart Disease , 2014, Front. Pediatr..

[91]  M. Wessels,et al.  Streptolysin O and NAD-Glycohydrolase Prevent Phagolysosome Acidification and Promote Group A Streptococcus Survival in Macrophages , 2014, mBio.

[92]  L. Zühlke,et al.  The case for global investment in rheumatic heart-disease control , 2014, Bulletin of the World Health Organization.

[93]  A. Boldt,et al.  The Lectin Pathway of Complement and Rheumatic Heart Disease , 2014, Front. Pediatr..

[94]  R. Root-Bernstein.  Rethinking Molecular Mimicry in Rheumatic Heart Disease and Autoimmune Myocarditis: Laminin, Collagen IV, CAR, and B1AR as Initial Targets of Disease , 2014, Front. Pediatr..

[95]  A. Fouet,et al.  The Innate Immune Response Elicited by Group A Streptococcus Is Highly Variable among Clinical Isolates and Correlates with the emm Type , 2014, PloS one.

[96]  Fangjia Lu,et al.  Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes. , 2014, Vaccine.

[97]  A. Blom,et al.  Scabies Mite Inactive Serine Proteases Are Potent Inhibitors of the Human Complement Lectin Pathway , 2014, PLoS neglected tropical diseases.

[98]  E. Baker,et al.  Structural Conservation, Variability, and Immunogenicity of the T6 Backbone Pilin of Serotype M6 Streptococcus pyogenes , 2014, Infection and Immunity.

[99]  Wen-long Jiang,et al.  Tumor necrosis factor-alpha 308G>A polymorphism and risk of rheumatic heart disease: a meta-analysis , 2014, Scientific Reports.

[100]  S. Kosanke,et al.  Identification of Streptococcal M-Protein Cardiopathogenic Epitopes in Experimental Autoimmune Valvulitis , 2014, Journal of Cardiovascular Translational Research.

[101]  Quanquan Ding,et al.  Ficolins and infectious diseases , 2014, Virologica Sinica.

[102]  A. Çengel,et al.  A Shift in the Balance of Regulatory T and T Helper 17 Cells in Rheumatic Heart Disease , 2014, Journal of Investigative Medicine.

[103]  G. Smyth,et al.  Susceptibility to Acute Rheumatic Fever Based on Differential Expression of Genes Involved in Cytotoxicity, Chemotaxis, and Apoptosis , 2013, Infection and Immunity.

[104]  J. Leckman,et al.  Brain Human Monoclonal Autoantibody from Sydenham Chorea Targets Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: Implications in Human Disease , 2013, The Journal of Immunology.

[105]  L. Guilherme,et al.  Rheumatic Heart Disease: Molecules Involved in Valve Tissue Inflammation Leading to the Autoimmune Process and Anti-S. pyogenes Vaccine , 2013, Front. Immunol..

[106]  E. Kaplan,et al.  Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement. , 2013, Global heart.

[107]  M. Crescenzi,et al.  Streptococcal–vimentin cross‐reactive antibodies induce microvascular cardiac endothelial proinflammatory phenotype in rheumatic heart disease , 2013, Clinical and experimental immunology.

[108]  Manisha Pandey,et al.  Strategies in the development of vaccines to prevent infections with group A streptococcus , 2013, Human vaccines & immunotherapeutics.

[109]  J. Carapetis,et al.  Group A streptococcal vaccines: paving a path for accelerated development. , 2013, Vaccine.

[110]  R. Kaslow,et al.  Structure of tumor necrosis factor-alpha haploblocks in European populations , 2013, Immunogenetics.

[111]  L. Guilherme,et al.  StreptInCor: A Candidate Vaccine Epitope against S. pyogenes Infections Induces Protection in Outbred Mice , 2013, PloS one.

[112]  A. Middelberg,et al.  Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). , 2013, Vaccine.

[113]  G. Maguire,et al.  Variability in disease burden and management of rheumatic fever and rheumatic heart disease in two regions of tropical Australia , 2013, Internal medicine journal.

[114]  Manisha Pandey,et al.  Long-Term Antibody Memory Induced by Synthetic Peptide Vaccination Is Protective against Streptococcus pyogenes Infection and Is Independent of Memory T Cell Help , 2013, The Journal of Immunology.

[115]  J. Nataro,et al.  Potential coverage of a multivalent M protein-based group A streptococcal vaccine. , 2013, Vaccine.

[116]  S. A. Palácios,et al.  CXCL9/Mig Mediates T cells Recruitment to Valvular Tissue Lesions of Chronic Rheumatic Heart Disease Patients , 2013, Inflammation.

[117]  A. Mohyuddin,et al.  A study on the association of TNF-α(-308), IL-6(-174), IL-10(-1082) and IL-1Ra(VNTR) gene polymorphisms with rheumatic heart disease in Pakistani patients. , 2013, Cytokine.

[118]  H. Vohra,et al.  Immune responsiveness during disease progression from acute rheumatic fever to chronic rheumatic heart disease. , 2012, Microbes and infection.

[119]  T. Parks,et al.  Streptococcal skin infection and rheumatic heart disease , 2012, Current opinion in infectious diseases.

[120]  A. Hofmann,et al.  Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. , 2012, Vaccine.

[121]  T. R. Peters,et al.  Detection of group A Streptococcus in tonsils from pediatric patients reveals high rate of asymptomatic streptococcal carriage , 2012, BMC Pediatrics.

[122]  D. Nelson,et al.  Cysteine proteinase SpeB from Streptococcus pyogenes – a potent modifier of immunologically important host and bacterial proteins , 2011, Biological chemistry.

[123]  T. Penfound,et al.  New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. , 2011, Vaccine.

[124]  A. Cheng,et al.  Acute post-streptococcal glomerulonephritis in the Northern Territory of Australia: a review of 16 years data and comparison with the literature. , 2011, The American journal of tropical medicine and hygiene.

[125]  A. Adeyemo,et al.  Genetic Susceptibility to Acute Rheumatic Fever: A Systematic Review and Meta-Analysis of Twin Studies , 2011, PloS one.

[126]  H. Sakata,et al.  Biofilm formation or internalization into epithelial cells enable Streptococcus pyogenes to evade antibiotic eradication in patients with pharyngitis. , 2011, Microbial pathogenesis.

[127]  Michael J Monteiro,et al.  Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[128]  J. Carapetis,et al.  Rheumatic fever in Indigenous Australian children , 2010, Journal of paediatrics and child health.

[129]  N. Shaikh,et al.  Prevalence of Streptococcal Pharyngitis and Streptococcal Carriage in Children: A Meta-analysis , 2010, Pediatrics.

[130]  R. Andrews,et al.  Prophylactic penicillin by the full moon: a novel approach in Central Australia that may help to reduce the risk of rheumatic heart disease. , 2010, Rural and remote health.

[131]  M. McDonald,et al.  Diversity of emm sequence types in group A beta-haemolytic streptococci in two remote Northern Territory Indigenous communities: implications for vaccine development. , 2010, Vaccine.

[132]  P. Smeesters,et al.  The streptococcal M protein: a highly versatile molecule. , 2010, Trends in microbiology.

[133]  H. White,et al.  Rheumatic heart disease in indigenous populations. , 2010, Heart, lung & circulation.

[134]  S. Blyth,et al.  An alternative technique for the induction of autoimmune valvulitis in a rat model of rheumatic heart disease. , 2010, Journal of immunological methods.

[135]  A. Khoruts,et al.  Induction of TGF-β1 and TGF-β1–dependent predominant Th17 differentiation by group A streptococcal infection , 2010, Proceedings of the National Academy of Sciences.

[136]  Dwight R. Johnson,et al.  The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[137]  L. Guilherme,et al.  A vaccine against S. pyogenes: design and experimental immune response. , 2009, Methods.

[138]  J. Carapetis,et al.  A Regional Initiative to Reduce Skin Infections amongst Aboriginal Children Living in Remote Communities of the Northern Territory, Australia , 2009, PLoS neglected tropical diseases.

[139]  J. Carapetis,et al.  Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. , 2009, The Lancet. Infectious diseases.

[140]  J. Kun,et al.  Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease , 2009, Clinical and experimental immunology.

[141]  G. S. Chhatwal,et al.  Autoantigens Identified by Screening a Human Heart cDNA Library with Acute Rheumatic Fever Sera , 2009, Annals of the New York Academy of Sciences.

[142]  D. Ustek,et al.  No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behçet’s disease , 2009, Clinical Rheumatology.

[143]  N. Ketheesan,et al.  B- and T-Cell Responses in Group A Streptococcus M-Protein- or Peptide-Induced Experimental Carditis , 2009, Infection and Immunity.

[144]  J. Carapetis,et al.  Some of the people, some of the time: susceptibility to acute rheumatic fever. , 2009, Circulation.

[145]  J. Carapetis,et al.  Disease burden and health-care clinic attendances for young children in remote aboriginal communities of northern Australia. , 2008, Bulletin of the World Health Organization.

[146]  M. Pichichero,et al.  Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[147]  M. van Lookeren Campagne,et al.  Macrophage complement receptors and pathogen clearance , 2007, Cellular microbiology.

[148]  J. Carapetis.  Rheumatic heart disease in developing countries. , 2007, The New England journal of medicine.

[149]  M. McDonald,et al.  Apparent contrasting rates of pharyngitis and pyoderma in regions where rheumatic heart disease is highly prevalent. , 2007, Heart, lung & circulation.

[150]  J. Musser,et al.  New understanding of the group A Streptococcus pathogenesis cycle. , 2007, Trends in microbiology.

[151]  A. Settin,et al.  Gene Polymorphisms of TNF-α−308, IL-10−1082, IL-6−174, and IL-1RaVNTR Related to Susceptibility and Severity of Rheumatic Heart Disease , 2007, Pediatric Cardiology.

[152]  S. Swedo,et al.  Tubulin Is a Neuronal Target of Autoantibodies in Sydenham’s Chorea1 , 2007, The Journal of Immunology.

[153]  J. Carapetis,et al.  Group A streptococcal infections in children , 2007, Journal of paediatrics and child health.

[154]  A. Bisno,et al.  Antecedent streptococcal infection in acute rheumatic fever. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[155]  M. McDonald,et al.  Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[156]  D. Jackson,et al.  Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. , 2006, The Journal of infectious diseases.

[157]  M. Juliano,et al.  Towards a Vaccine Against Rheumatic Fever , 2006, Clinical & developmental immunology.

[158]  J. Carapetis,et al.  B‐cell antigen D8/17 is a marker of rheumatic fever susceptibility in Aboriginal Australians and can be tested in remote settings , 2006, The Medical journal of Australia.

[159]  J. Langley,et al.  A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults , 2006 .

[160]  M. Cunningham.  Molecular mimicry, autoimmunity and infection in the pathogenesis of rheumatic fever , 2006 .

[161]  Fredric Carlsson,et al.  Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non‐opsonic epitopes , 2006, Molecular microbiology.

[162]  Edward A Graviss,et al.  Genome-Wide Analysis of Group A Streptococci Reveals a Mutation That Modulates Global Phenotype and Disease Specificity , 2006, PLoS pathogens.

[163]  R. Fujinami,et al.  Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease , 2006, Clinical Microbiology Reviews.

[164]  P. Cleary,et al.  Active and Passive Intranasal Immunizations with Streptococcal Surface Protein C5a Peptidase Prevent Infection of Murine Nasal Mucosa-Associated Lymphoid Tissue, a Functional Homologue of Human Tonsils , 2005, Infection and Immunity.

[165]  J. Carapetis,et al.  The global burden of group A streptococcal diseases. , 2005, The Lancet. Infectious diseases.

[166]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[167]  M. Davies,et al.  Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. , 2005, The Journal of infectious diseases.

[168]  O. Yeǧin,et al.  TNF-alpha G-308A polymorphism is associated with rheumatic fever and correlates with increased TNF-alpha production. , 2005, Journal of autoimmunity.

[169]  F. Tsai,et al.  Lack of association of genetic polymorphisms in the interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 genes with risk of rheumatic heart disease in Taiwan Chinese. , 2005, International heart journal.

[170]  W. Edwards,et al.  Calcified Rheumatic Valve Neoangiogenesis Is Associated With Vascular Endothelial Growth Factor Expression and Osteoblast-Like Bone Formation , 2005, Circulation.

[171]  H. Çelik,et al.  TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children , 2005, Journal of Molecular Medicine.

[172]  L. Guilherme,et al.  Rheumatic Fever: How S. pyogenes‐Primed Peripheral T Cells Trigger Heart Valve Lesions , 2005, Annals of the New York Academy of Sciences.

[173]  Kevin F. Jones,et al.  Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine , 2005, Infection and Immunity.

[174]  A. Toubert,et al.  How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease. , 2005, Journal of autoimmunity.

[175]  L. Guilherme,et al.  Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. , 2004, The American journal of pathology.

[176]  James D. Campbell,et al.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. , 2004, JAMA.

[177]  J. McCarthy,et al.  Scabies: more than just an irritation , 2004, Postgraduate medical journal.

[178]  M. McDonald,et al.  Acute rheumatic fever: a chink in the chain that links the heart to the throat? , 2004, The Lancet. Infectious diseases.

[179]  Dwight R. Johnson,et al.  Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. , 2003, The Journal of infectious diseases.

[180]  M. Rohde,et al.  Intracellular Survival of Streptococcus pyogenes in Polymorphonuclear Cells Results in Increased Bacterial Virulence , 2003, Infection and Immunity.

[181]  J. Granados,et al.  Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with rheumatic heart disease. , 2003, Journal of autoimmunity.

[182]  M. Davies,et al.  Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. , 2003, The Journal of infectious diseases.

[183]  P. Majcherczyk,et al.  Proinflammatory Activity of Cell-wall Constituents from Gram-positive Bacteria , 2003, Scandinavian journal of infectious diseases.

[184]  L. Guilherme,et al.  Rheumatic fever: the T cell response leading to autoimmune aggression in the heart. , 2002, Autoimmunity reviews.

[185]  F. Shann,et al.  Systematic review of rheumatic heart disease prevalence in children in developing countries: The role of environmental factors , 2002, Journal of paediatrics and child health.

[186]  L. Harel,et al.  Presence of the d8/17 B‐cell marker in children with rheumatic fever in Israel , 2002, Clinical genetics.

[187]  G. Stollerman,et al.  Rheumatic fever in the 21st century. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[188]  A. Sette,et al.  T-Cell Reactivity against Streptococcal Antigens in the Periphery Mirrors Reactivity of Heart-Infiltrating T Lymphocytes in Rheumatic Heart Disease Patients , 2001, Infection and Immunity.

[189]  V. Fischetti,et al.  Induction of Autoimmune Valvular Heart Disease by Recombinant Streptococcal M Protein , 2001, Infection and Immunity.

[190]  A. Toubert,et al.  Heart-directed autoimmunity: the case of rheumatic fever. , 2001, Journal of autoimmunity.

[191]  Bruce A. Roe,et al.  Complete genome sequence of an M1 strain of Streptococcus pyogenes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[192]  S. Hamada,et al.  Systemic and Mucosal Immunizations with Fibronectin-Binding Protein FBP54 Induce Protective Immune Responses against Streptococcus pyogenes Challenge in Mice , 2001, Infection and Immunity.

[193]  C. Duran,et al.  Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. , 2001, The Journal of infectious diseases.

[194]  M. Pichichero,et al.  Fewer symptoms occur in same-serotype recurrent streptococcal tonsillopharyngitis. , 2000, Archives of otolaryngology--head & neck surgery.

[195]  M. Rohde,et al.  Pharyngeal carriage of group C and group G streptococci and acute rheumatic fever in an Aboriginal population , 2000, The Lancet.

[196]  J. Carapetis,et al.  Skin infections and infestations in Aboriginal communities in northern Australia , 2000, The Australasian journal of dermatology.

[197]  M. Cunningham.  Pathogenesis of Group A Streptococcal Infections , 2000, Clinical Microbiology Reviews.

[198]  D. Jackson,et al.  New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population , 2000, Nature Medicine.

[199]  L. Sadler,et al.  Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves , 2000, BJOG : an international journal of obstetrics and gynaecology.

[200]  M. Cunningham,et al.  Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. , 2000, The Journal of clinical investigation.

[201]  H. Courtney,et al.  New protective antigen of group A streptococci. , 1999, The Journal of clinical investigation.

[202]  M. Cunningham,et al.  Molecular analysis of polyreactive monoclonal antibodies from rheumatic carditis: human anti-N-acetylglucosamine/anti-myosin antibody V region genes. , 1998, Journal of immunology.

[203]  M. Rennels,et al.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Pediatrics.

[204]  M. Good,et al.  Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. , 1997, Vaccine.

[205]  M. Good,et al.  Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. , 1997, International immunology.

[206]  S. Kosanke,et al.  Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein , 1997, Infection and immunity.

[207]  L. Engstrand,et al.  Intracellular Reservoir of Streptococcus pyogenes In Vivo: A Possible Explanation for Recurrent Pharyngotonsillitis , 1997, The Laryngoscope.

[208]  E. Meals,et al.  STREPTOCOCCAL PYROGENIC EXOTOXINS A (SpeA) AND C (SpeC) STIMULATE THE PRODUCTION OF INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS) PROTEIN IN RAW 264.7 MACROPHAGES , 1995, Shock.

[209]  C. Phornphutkul,et al.  Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci , 1994, The Lancet.

[210]  M. Cunningham,et al.  Cloning and sequence analysis of a gene encoding a 67-kilodalton myosin-cross-reactive antigen of Streptococcus pyogenes reveals its similarity with class II major histocompatibility antigens , 1994, Infection and immunity.

[211]  M. Cunningham,et al.  Immunological mimicry between N-acetyl-beta-D-glucosamine and cytokeratin peptides. Evidence for a microbially driven anti-keratin antibody response. , 1994, Journal of immunology.

[212]  S. Shulman.  Severe group A streptococcal infections. , 1993, Critical care medicine.

[213]  C. Gauntt,et al.  Alpha-helical coiled-coil molecules: a role in autoimmunity against the heart. , 1993, Clinical immunology and immunopathology.

[214]  L. Guilherme,et al.  Association of Human Leukocyte Class II Antigens With Rheumatic Fever or Rheumatic Heart Disease in a Brazilian Population , 1991, Circulation.

[215]  M. Cunningham,et al.  A new heart-cross-reactive antigen in Streptococcus pyogenes is not M protein. , 1990, The Journal of infectious diseases.

[216]  V. Fischetti,et al.  Streptococcal M protein: molecular design and biological behavior , 1989, Clinical Microbiology Reviews.

[217]  R. Williams,et al.  Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. , 1989, The Journal of clinical investigation.

[218]  P. Duff,et al.  Rheumatic heart disease in pregnancy. , 1989, Clinical obstetrics and gynecology.

[219]  C. Restrepo,et al.  Aschoff bodies of rheumatic carditis are granulomatous lesions of histiocytic origin. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[220]  R. Marcus,et al.  Aberrant expression of HLA-DR antigen on valvular fibroblasts from patients with active rheumatic carditis. , 1986, Clinical and experimental immunology.

[221]  C. Marboe,et al.  Monoclonal antibody identification of mononuclear cells in endomyocardial biopsy specimens from a patient with rheumatic carditis. , 1985, Human pathology.

[222]  Quinn Rw.  Epidemiology of group A streptococcal infections--their changing frequency and severity. , 1982 .

[223]  E. N. Fox,et al.  Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. , 1978, The Journal of infectious diseases.

[224]  E. N. Fox,et al.  Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract. , 1975, The Journal of infectious diseases.

[225]  E. N. Fox,et al.  Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. , 1973, The Journal of clinical investigation.

[226]  L. Wannamaker,et al.  The Chain that Links the Heart to the Throat , 1973, Circulation.

[227]  B. F. Massell,et al.  Rheumatic fever following streptococcal vaccination. Report of three cases. , 1969, JAMA.

[228]  B. Wedum,et al.  Origin of the Aschoff Body , 1963, Annals of the rheumatic diseases.

[229]  R. Lancefield.  Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.

[230]  A. Davies,et al.  Heredity, infection and chemoprophylaxis in rheumatic carditis: an epidemiological study of a communal settlement , 1960, Journal of Hygiene.

[231]  R. Lancefield.  PERSISTENCE OF TYPE-SPECIFIC ANTIBODIES IN MAN FOLLOWING INFECTION WITH GROUP A STREPTOCOCCI , 1959, The Journal of experimental medicine.

[232]  T. Duckett Jones,et al.  THE DIAGNOSIS OF RHEUMATIC FEVER , 1944 .

[233]  L. Gross,et al.  Studies on the Myocardial Aschoff Body: I. Descriptive Classification of Lesions. , 1934, The American journal of pathology.

[234]  R. Lancefield.  A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI , 1933, The Journal of experimental medicine.

[235]  R. Lancefield.  THE ANTIGENIC COMPLEX OF STREPTOCOCCUS HAEMOLYTICUS : I. DEMONSTRATION OF A TYPE-SPECIFIC SUBSTANCE IN EXTRACTS OF STREPTOCOCCUS HAEMOLYTICUS. , 1927, The Journal of experimental medicine.

[236]  P. Pohlner,et al.  Interventional Management of Indigenous Rheumatic Valvular Heart Disease at TPCH , 2019, Heart, Lung and Circulation.

[237]  R. Baker,et al.  Outcomes of Redo Valve Surgery in Indigenous Australians. , 2019, Heart, lung & circulation.

[238]  A. Abdallah,et al.  IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients , 2015, Pediatric Cardiology.

[239]  Elise R Breed,et al.  Autoimmune Valvular Carditis , 2014, Current Allergy and Asthma Reports.

[240]  A. Ralph,et al.  Group a streptococcal diseases and their global burden. , 2013, Current topics in microbiology and immunology.

[241]  L. Guilherme,et al.  Genes, autoimmunity and pathogenesis of rheumatic heart disease , 2011, Annals of pediatric cardiology.

[242]  E. Bonfá,et al.  Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. , 2010, Cytokine.

[243]  L. Guilherme,et al.  Rheumatic Fever and Rheumatic Heart Disease: Cellular Mechanisms Leading Autoimmune Reactivity and Disease , 2009, Journal of Clinical Immunology.

[244]  J. Zabriskie,et al.  Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. , 2006, The Journal of infectious diseases.

[245]  R. Anders,et al.  Mapping a conserved conformational epitope from the M protein of group A streptococci. , 1996, Peptide research.

[246]  L. G. Veasy,et al.  Persistence of acute rheumatic fever in the intermountain area of the United States. , 1994, The Journal of pediatrics.

[247]  R. Quinn.  Epidemiology of group A streptococcal infections--their changing frequency and severity. , 1982, The Yale journal of biology and medicine.

[248]  J. Glover.  Milroy Lectures on the Incidence of Rheumatic Diseases. III. The Incidence of Chronic Arthritis. , 1930 .